A p38 MAP kinase inhibitor suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss through the inhibition of bone turnover.
Xu C, Wei Z, Dong X, Xing J, Meng X, Qiu Y, Zhou H, Zheng W, Xu Z, Huang S, Xia W, Lv L, Jiang H, Wang W, Zhao X, Liu Z, Akimoto Y, Zhao B, Wang S, Hu Z.
Xu C, et al. Among authors: xu z.
Biochem Pharmacol. 2024 Jun 22:116391. doi: 10.1016/j.bcp.2024.116391. Online ahead of print.
Biochem Pharmacol. 2024.
PMID: 38914317